Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Mepivacaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexivacaine SCHEMBL34247 | 1.00 | KCNK3 (0.70) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL30335090 | 1.00 | KCNK3 (0.70) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL34245 | 1.00 | KCNK3 (0.70) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL34246 | 0.99 | KCNK3 (0.72) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL25314 | 0.99 | KCNK3 (0.72) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Dexivacaine SCHEMBL25315 | 0.99 | KCNK3 (0.72) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL2565234 | 0.97 | KCNK3 (0.70) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL5685622 | 0.97 | KCNK3 (0.70) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| Mepivacaine SCHEMBL2553896 | 0.96 | KCNK3 (0.69) | KCNK3LMNACYP3A4CYP2D6KCNH2 | |
| SCHEMBL18485518 | 0.94 | CYP3A4 (0.74) | KCNK3LMNACYP3A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576138-B2 | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2026-03-17 | — | — | US | disclosed |
| EP-4637926-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2025-10-29 | — | — | EP | disclosed |
| CN-114729004-B | Heterocyclic compounds | 日商泛美克斯股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20250115655-A1 | PHARMACEUTICALS AND DEVICES FOR THE COVALENT IMMOBILIZATION TO THE EXTRACELLULAR MATRIX BY TRANSGLUTAMINASE | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2025-04-10 | — | — | US | disclosed |
| EP-3645559-B1 | PHARMACEUTICALS AND DEVICES FOR THE COVALENT IMMOBILIZATION TO THE EXTRACELLULAR MATRIX BY TRANSGLUTAMINASE | UNIV WUERZBURG J MAXIMILIANS (DE) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024132278-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-20230414507-A1 | CD1D-LIGAND-COMPOUND-CONTAINING LIPOSOME PREPARATION HAVING IMPROVED PHARMACOKINETICS | REGIMMUNE CORPORATION (JP) | 2023-12-28 | — | — | US | disclosed |
| EP-4257140-A1 | CD1D-LIGAND-COMPOUND-CONTAINING LIPOSOME PREPARATION HAVING IMPROVED PHARMACOKINETICS | Regimmune Corporation (JP) | 2023-10-11 | — | — | EP | disclosed |
| EP-3668867-B1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS | UNIV REGENSBURG (DE) | 2023-10-04 | — | — | EP | disclosed |
| EP-1694296-A1 | INJECTABLE COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| EP-1640008-A1 | A stabilized aqueous (6S)-folinic acid preparation for injection | Nipro Corporation (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20060058312-A1 | Stabilized aqueous preparation for injection | NIPRO CORPORATION (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1618894-A1 | COMPOSITION FOR INJECTION | Takeda Pharmaceutical Company Limited (JP) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005058277-A1 | INJECTABLE COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-06-30 | — | — | WO | disclosed |
| US-20030191157-A1 | Injections | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1310252-A1 | INJECTIONS | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-4514403-A | NONHABIT-FORMING CENTRALLY ACTING ANALGESIC | YOSHITOMI PHARMACEUTICAL INDUSTRIES LTD. (JP) | 1985-04-30 | — | — | US | disclosed |
| EP-0047990-B1 | HYDROURACIL COMPOUNDS | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1984-01-25 | — | — | EP | disclosed |
| EP-0047990-A1 | Hydrouracil compounds | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576138-B2 | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase | MSTN, MYOF, IGFBP1 | KCNK3 4465/4885LMNA 850/4885CYP3A4 4800/4885 |
| US-20230414507-A1 | CD1D-LIGAND-COMPOUND-CONTAINING LIPOSOME PREPARATION HAVING IMPROVED PHARMACOKINETICS | KLRK1, LDLR, NPC1L1 | KCNK3 997/4885LMNA 2362/4885CYP3A4 2801/4885 |
| US-20030191157-A1 | Injections | MPI, SI, GANAB | KCNK3 2332/4885LMNA 2256/4885CYP3A4 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.